SPONSOR

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Total Trials

Recruiting

Phases

Phase 2, EARLY_Phase 1, Phase 3, Phase 1, Phase 2

Conditions studied: Brain Neoplasms Eloquent Area Brain Tumors Esophagus Cancer Colorectal Cancer HR+/HER2- Advanced Breast Cancer Targeted Therapy Gastric Cancer Nerve Sheath Tumor Refractory Solid Tumors Relapsed Solid Tumors

Cancer Institute and Hospital, Chinese Academy of Medical Sciences is a clinical research sponsor with 20 registered studies on ClinicalTrials.gov, of which 20 are actively recruiting participants. Research covers conditions including Brain Neoplasms, Eloquent Area Brain Tumors, Esophagus Cancer, Colorectal Cancer.

The trial portfolio spans Phase 2, EARLY_Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

How many clinical trials has Cancer Institute and Hospital, Chinese Academy of Medical Sciences sponsored?

ClinicalMetric currently tracks 20 clinical trials sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, of which 20 are actively recruiting participants. These trials cover conditions including Brain Neoplasms, Eloquent Area Brain Tumors, Esophagus Cancer. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Cancer Institute and Hospital, Chinese Academy of Medical Sciences research focus on?

Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trials span Brain Neoplasms, Eloquent Area Brain Tumors, Esophagus Cancer, Colorectal Cancer, HR+/HER2- Advanced Breast Cancer, and additional conditions. The research pipeline includes Phase 2, EARLY_Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences clinical trial?

To participate in a Cancer Institute and Hospital, Chinese Academy of Medical Sciences trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Cancer Institute and Hospital, Chinese Academy of Medical Sciences trials with current recruitment status updated daily.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Frequently Asked Questions — Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Clinical Trials by Cancer Institute and Hospital, Chinese Academy of Medical Sciences

CONNEctome-guided Navigation for Eloquent-area Tumor Surgery Trial

Neoadjuvant Comprehensive Treatment for Unresectable Esophageal Cancer

Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study

Chidamide/Everolimus for PIK3CA Wild-type/Mutant HR+/HER2- Advanced Breast Cancer

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

Personalized KSX01-TCRT in Patients With Advanced Solid Tumors

RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma

Multi-Reader Multi-Case Trial Evaluating Computer-Aided Tool for Prognostic Prediction of Colorectal Liver Metastases

Postoperative Management for HNSCC Based on Pathological Response of Induction Chemotherapy and Immunotherapy

XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC

Response-Based Local Therapy for Regionally Advanced Breast Cancer

Nanoliposomal Irinotecan, Oxaliplatin Plus Capecitabine As Conversion Therapy of Locally Advanced Colorectal Cancer

Prospective Validation and Application of an Artificial Intelligence-based Model for Evaluating the Efficacy of Breast Cancer Patients After Neoadjuvant Therapy

Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis

CTR-FAPI-guided Precision Surgery for Newly Diagnosed MTC

LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer